BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) is a Healthcare company (Biotechnology) with a market capitalization of $440M. The Maz Rating grades it against the other companies in its sector.
BlossomHill Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $15.13, BlossomHill Therapeutics, Inc. trades at 13.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -146.3%, return on invested capital of -30.7% and a free cash flow yield of -15.1%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 12.82. Over the past 52 weeks the share price ranged from $11.02 to $27.99, with a beta of 0.00.
BlossomHill Therapeutics, Inc. does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.